44 results on '"Bensimon, Cécile M."'
Search Results
2. A brain-based definition of death and criteria for its determination after arrest of circulation or neurologic function in Canada: a 2023 clinical practice guideline
3. Pediatrics
4. The promises and limitations of codes of medical ethics as instruments of policy change
5. Justifying the Initiation and Continued Provision of Public Health Interventions in Humanitarian Settings
6. A history of quarantine
7. Surgical Site Infection Prevention: A Qualitative Analysis of an Individualized Audit and Feedback Model
8. The duty to care in an influenza pandemic: A qualitative study of Canadian public perspectives
9. Informal coercion in psychiatry: a focus group study of attitudes and experiences of mental health professionals in ten countries
10. The Role of Faith-Based Organizations in the Ethical Aspects of Pandemic Flu Planning—Lessons Learned from the Toronto SARS Experience
11. Pediatrics
12. Restrictive Measures in an Influenza Pandemic: A Qualitative Study of Public Perspectives
13. Your Liberty or Your Life: Reciprocity in the Use of Restrictive Measures in Contexts of Contagion
14. Developing Sustainability: A New Metaphor for Progress
15. A qualitative study of the duty to care in communicable disease outbreaks
16. The care delivery experience of hospitalized patients with complex chronic disease
17. Your Liberty or Your Life: Reciprocity in the Use of Restrictive Measures in Contexts of Contagion
18. SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCE11This case study was written by Cécile M. Bensimon under the supervision of Peter Singer, following interviews they conducted with Sciona executives and ethics consultants in November 2002. We would like to acknowledge Martin Tierney's work on the study, and Abdallah Daar, Margaret Eaton and David Finegold provided constructive comments and edits on earlier drafts. This case study is one in a series produced under a grant by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Unless otherwise specified, all attributed quotes were obtained during the case study interviews. We would like to thank all who participated in the case study, especially Rosalynn Gill-Garrison, whose invaluable assistance enabled us to complete this study.
19. PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTS11This case study was written by David Finegold based on interviews he conducted with Pipeline employees and a company consultant. Interviews were conducted by phone or at the Keck Graduate Institute in Claremont, California in April to June 2004. Unless otherwise specified, all quotations were obtained during these interviews. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Grateful appreciation is extended to all those who participated and assisted in this case study, especially to Rasmus Nelund, without whose efforts this case study could not have been written.
20. MERCK: STAYING THE COURSE11The case study was written by David Finegold based on interviews he conducted with Margaret Eaton and Jocelyn E. Mackie at Merck on March 30-31, 2004 at company headquarters in Whitehouse Station, NJ and Merck's Research Laboratories in Rahway, NJ. Unless otherwise specified, all quotes attributed to these people were obtained during interviews. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Everyone's participation, suggestions, and assistance are greatly appreciated. Special thanks are extended to Samir Khalil for arranging the visit.
21. PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARD11This case study is of a real company that has been anonymized because the firm was acquired after the case was completed. The case study was written by Cécile M. Bensimon and David Finegold based on interviews they conducted on September 26, 2002 at Company headquarters. Four members of the company's EAB were also interviewed by phone. Unless otherwise specified, all quotes attributed to these people were obtained during interviews. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. The participation, suggestions, and assistance of all involved are greatly appreciated.
22. TGN BIOTECH: A START-UP WITH ETHICAL ROOTS11This case was written by Jocelyn E. Mackie under the supervision of Abdallah S. Daar and with the assistance of Cécile M. Bensimon. All information, unless otherwise stated, was gathered from personal interviews of employees at TGN Biotech in August 2003 conducted by Mackie, Daar, and Bensimon. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Grateful appreciation is extended to all who participated and assisted in this case study, without whose efforts this case study could not have been written.
23. DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPS11The case study was written by Cécile M. Bensimon and David Finegold based on interviews they conducted with Béatrice Godard between February 2003 and November 2004. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Grateful appreciation is extended to all those who participated and assisted in this case study. Special thanks are extended to Leif Christoffersen for invaluable his assistance in this case.
24. MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUES11This case study was written by David Finegold based on interviews he conducted with employees and a company consultant. Interviews were conducted with Beatrice Godard at Maxim and by phone in April 2003. Unless otherwise specified, all quotes were obtained during these interviews. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Grateful appreciation is extended to all those who participated and assisted in this case study, especially to Larry Stambaugh, without whose efforts this case study could not have been written.
25. INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIP11This case study was written by David Finegold based on interviews conducted on October 1, 2003 at Interleukin in Waltham, Massachusetts. Unless otherwise specified, all quotations that appear in the case were obtained during these interviews. Interviews were conducted by Finegold, Jocelyn Mackie, and Cécile M. Bensimon. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. We would especially like to thank Rahul Dhanda without whose help this case study would not have been possible.
26. MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUES11The case study was written by Margaret L. Eaton based on interviews with 10 Millennium employees on September 25, 2002 at company headquarters. Interviews were conducted with David Finegold, who also gave valuable editing assistance. Rahul Dhanda provided important insights and Emily Taylor collected and provided helpful background materials. This case study is one in a series produced under a grant funded by The Seaver Institute and Genome Canada to study models of informed ethical decision making in bioscience firms. Grateful appreciation is extended to all those who participated and assisted, especially to Millennium's Gary Cohen, without whose efforts this case study could not have been written.
27. GENZYME: PUTTING PATIENTS FIRST11This case study was written by David Finegold and Jocelyn Mackie based on interviews conducted at Genzyme on September 30 and October 1, 2003 at Genzyme's headquarters in Cambridge, Massachusetts. Unless otherwise specified, all quotes in the case were obtained during interviews. Interviews were conducted by Finegold, Mackie and Cæcile Bensimon. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. We would like to thank all those who partcipated in this study, especially Elliott Hillback for his help in arranging the case study and detailed feedback on the earlier drafts of the study.
28. CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUES
29. RESEARCH TEAM
30. NOVO NORDISK: THE TRIPLE BOTTOM LINE11This case study was written by Jocelyn E. Mackie under the supervision of Abdallah S. Daar. All data for this case come from interviews performed by Daar and Mackie on March 15–17, 2004, at Novo Nordisk, unless otherwise noted. This case is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. We would like to thank all the employees of Novo Nordisk who took part in this study.
31. INTRODUCTION
32. AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICE11This case study was written by Margaret L. Eaton based on interviews with three Affymetrix employees and five ethics advisors in July and August 2003. Two of the interviews were conducted with David Finegold, who also gave valuable assistance in editing this case study, as did Abdallah Daar. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring informed ethical decision making in bioscience firms. Grateful appreciation is extended to all those who participated and assisted, especially to Affymetrix's Katie Tillman Buck, without whose efforts this case study could not have been written.
33. MONSANTO COMPANY: BIO-AGRICULTURE PIONEER11The case study was written by Cécile M. Bensimon under the supervision of Peter Singer, following interviews they conducted with Monsanto executives in December 2002 at company headquarters in St. Louis, Mo. Abdallah Daar, Margaret Eaton and David Finegold, provided constructive comments and edits on earlier drafts. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Unless otherwise specified, all attributed quotes were obtained during the case study interviews. We would like to thank all the Monsanto executives who participated in the case, especially Gerard Barry, whose invaluable assistance enabled us to complete this study.
34. Priority setting of ICU resources in an influenza pandemic: a qualitative study of the Canadian public's perspectives
35. Life Interrupted: The Impact of Complex Chronic Disease from the Perspective of Hospitalized Patients
36. Duty to Care Scenario
37. Priority Setting Scenario Measure
38. Restrictive Measures Scenario and Question Guide
39. Perceived barriers to therapeutic hypothermia for patients resuscitated from cardiac arrest: A qualitative study of emergency department and critical care workers*
40. Evidence and Effectiveness in Decisionmaking for Quarantine
41. On pandemics and the duty to care: whose duty? who cares?
42. Identifying Prioritization Criteria to Supplement Critical Care Triage Protocols for the Allocation of Ventilators during a Pandemic Influenza.
43. On pandemics and the duty to care: whose duty? who cares?
44. Stakeholders' views about cardiac report cards: a qualitative study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.